NEJM: Modern's vaccine is more effective than Pfizer's

In a new study published yesterday (Wednesday) in the New England Journal of Medicine and reported by the New York Times , a comparison was made “in the real world” between the effectiveness of a company’s vaccine Pfizer compared to that of a modern company. While the two innovative mRNA-based vaccines have been approved for use it has been said that in terms of efficacy they are both equal. But now it turns out from the new study that the data indicate a little differently: there is a difference, even if it is small, in favor of a “modern” vaccine.

Roughly speaking, about 221 million doses of the “Pfizer” vaccine have already been issued For vaccination in the United States, compared to about 150 million of the “Modern” vaccine. About five comparative studies have been published recently, the most recent of which, as stated in “New England”, and the conclusion that emerges from them: Vaccination “Modern” seems to provide greater protection than the Pfizer vaccine months after the injection.

The latest study evaluated efficacy in the “real world” to prevent symptomatic disease among about 5,000 health care professionals And nurses in 25 U.S. states. The effectiveness of the Pfizer vaccine was found to be 88.8%, while that of the Modern is 96.3%. It was also found that the effectiveness of a “modern” vaccine for the prevention of serious illness is in the range of between 92% and 100%, with the Pfizer vaccine lagging behind by about 15% -10%. It was also found that compared to the Delta variant, the “Modern” vaccine is about 30% more effective in prevention.

It was also found that the “Pfizer” vaccine produces one-third to one-half less antibody levels than the one that “Modern” vaccine but the gap is negligible because there are often more than 100 times differences in antibody levels between two healthy people anyway. “Modern” has asked the FDA for approval to give a booster (third dose) at a dose of 50 micrograms – about half the dose of the second dose because the second dose still raises the levels of antibodies in the vaccinated body long after it has been given.

If the gap in efficiency continues to widen, this will also have implications for the debate currently taking place in the US in the context of the booster dose, scientists. Although the difference is not large, it is consistent.

Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
If You're Waiting to Stream <em>Scream</em> Here’s What to Know thumbnail

If You’re Waiting to Stream Scream Here’s What to Know

When the first Scream debuted back in 1996, it faced an almost insurmountable pressure to succeed, amidst a sea of cliche slashers in what was an—at the time—often-maligned horror subgenre. Following the success of multiple franchises in the 70’s and 80’s including Nightmare on Elm Street and Halloween, sequels and knockoffs had made it so…
Read More
Zurich health director Rickli promises: By the beginning of February, everyone who wants will be boosted - the most important questions and answers about vaccination thumbnail

Zurich health director Rickli promises: By the beginning of February, everyone who wants will be boosted – the most important questions and answers about vaccination

In Zürich sind 511 000 Drittimpfungen verabreicht worden. Seit 1. Januar gilt die vom Bund empfohlene Frist von vier Monaten. Eine Übersicht. Seit dem 3. Januar können Kinder zwischen 5 und 11 Jahren im Kanton Zürich für die Impfung angemeldet werden. Emily Elconin / Bloomberg Alle weiteren Nachrichten zum Coronavirus in der Schweiz finden Sie in unserer Übersicht.…
Read More
Vaccine expected to induce strong immune responses against 2022 monkeypox virus, research shows thumbnail

Vaccine expected to induce strong immune responses against 2022 monkeypox virus, research shows

The figure shows that, for two example proteins that are targeted by VACV-vaccine-induced antibodies, the 2022 monkeypox virus (MPXV-2022) does not comprise any new mutations relative to the previously observed monkeypox virus (MPXV-CB). Credit: HKUST & UoM New research has suggested that recommended vaccinia virus (VACV)-based vaccines will mount a robust immune response against the
Read More
COVID's Assault on the Moral Fiber of Medicine thumbnail

COVID’s Assault on the Moral Fiber of Medicine

COVID-19's fourth surge is testing the moral fiber of American medicine. The virus has infected more than 42 million Americans and claimed more than 675,000 lives in less than 2 years. Now the Delta variant is forcing us to once again face an onslaught of critically ill patients while at the same time delaying routine…
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share